Outcomes of critically ill COVID-19 survivors and caregivers: a case study-centred narrative review

Devenir des survivants et des soignants gravement atteints par la COVID-19 : une revue narrative centrée sur une étude de cas

Michelle E. Kho, PT, PhD • Oleksa G. Rewa, MD, MSc • J. Gordon Boyd, MD, PhD • Karen Choong, MB, BCh, MSc • Graeme C. H. Stewart, BPAPM (c) • Margaret S. Herridge, MS, MD, MPH

Received: 15 March 2021 / Revised: 10 November 2021 / Accepted: 22 November 2021 / Published online: 31 January 2022
© Canadian Anesthesiologists’ Society 2022

Abstract

Purpose Critical illness is a transformative experience for both patients and their family members. For COVID-19 patients admitted to the intensive care unit (ICU), survival may be the start of a long road to recovery. Our knowledge of the post-ICU long-term sequelae of acute respiratory distress syndrome (ARDS) and severe acute respiratory syndrome (SARS) may inform our understanding and management of the long-term effects of COVID-19.

Source We identified international and Canadian epidemiologic data on ICU admissions for COVID-19, COVID-19 pathophysiology, emerging ICU practice patterns, early reports of long-term outcomes, and federal support programs for survivors and their families. Centred around an illustrating case study, we applied relevant literature from ARDS and SARS to contextualize knowledge within emerging COVID-19 research and extrapolate findings to future long-term outcomes.

Principal findings COVID-19 is a multisystem disease with unknown long-term morbidity and mortality. Its pathophysiology is distinct and unique from ARDS, SARS, and critical illness. Nevertheless, based on initial reports of critical care management for COVID-19 and the varied injurious supportive practices employed in the ICU, patients and families are at risk for post-intensive care syndrome. The distinct incremental risk of COVID-19 multiple organ dysfunction is unknown. The risk of mood disorders in family members may be further exacerbated by imposed isolation and stigma.

Conclusion Emerging literature on COVID-19 outcomes suggests some similarities with those of ARDS/SARS and prolonged mechanical ventilation. The pathophysiology of COVID-19 is presented here in the context of early outcome data and to inform an agenda for longitudinal research for patients and families.
COVID-19 outcomes

COVID-19 is a multisystem disease with unknown recovery and long-term outcomes. Early systematic reviews documented 42% mortality, but more adult patients with COVID-19 are now surviving their intensive care unit (ICU) stay, with a pooled 36% mortality rate. Survivors typically experience long hospital and ICU lengths of stay (LOS). An early systematic review of 52 international studies of hospitalized patients admitted between December 2019 and April 2020 documented a median hospital LOS varying from five to 29 days. This is consistent with hospital data from seven sites in the Toronto and Mississauga areas in the GEMINI network. Canadian ICU cohorts reported hospital LOS varying from 17 to 18 days, and ICU LOS from 9 to 11 days (Table 1). Longer ICU LOS increases the risk of disability after ICU and hospital discharge.

Research from severe acute respiratory syndrome (SARS) and acute respiratory distress syndrome (ARDS) may help to anticipate short- and long-term challenges faced by COVID-19 survivors and their caregivers. ICU survivors of COVID-19 are at particular risk for complex multimorbidities, weakness and physical disability, cognitive dysfunction, and mood disorders for both patients and families. This narrative review presents a case study of a composite critically ill adult patient with COVID-19, from ICU admission through to recovery and return to the community. We identified peer-reviewed international and Canadian epidemiologic data and cohort studies from PubMed and Canadian government websites for data on ICU admissions for COVID-19, COVID-19 pathophysiology, emerging ICU practice patterns, and early reports of long-term outcomes. We summarize federal support programs for survivors and their families from government websites. Throughout the course of this case, we highlight key discussion points in ICU management and summarize the supportive evidence, relevant pathophysiology, and potential implications for outcome-based ICU survivorship research.

Case study: initial ICU management

Ms. Z. is a 45-yr-old functionally independent woman who worked full-time in a senior government position. Her medical history includes hypertension and type II diabetes with mild renal impairment. Ten days after diagnosis at a walk-in COVID-19 centre, she presented to an emergency room with shortness of breath and progressive hypoxic respiratory failure, requiring urgent intubation and admission to the ICU. She was given 6 mg dexamethasone daily, deeply sedated with propofol and fentanyl, and pharmacologically paralyzed. Despite optimized, lung-protective ventilation settings, she remained hypoxic with an arterial partial pressure of oxygen/fraction of inspired oxygen ratio (PaO₂/FiO₂; P/F ratio) of 60. She was prone with good effect and this continued intermittently for 1 week. She received broad-spectrum antimicrobials for documented ventilator-associated pneumonia (Klebsiella pneumoniae).
Table 1  Canadian critical care cohorts of patients with COVID-19

| Cohort          | Vancouver<sup>a</sup> | Montreal<sup>b</sup> | CAN-SARI<sup>c</sup> |
|-----------------|------------------------|----------------------|-----------------------|
| N               | 117                    | 75                   | 328 (ICU only)        |
| Number of centres | 6                      | 1                    | 33                    |
| ICU types       | Medical-surgical; quaternary ($n = 1$), tertiary ($n = 3$), community ($n = 2$) | Medical-surgical; quaternary | Medical surgical; academic ($n = 15$); community ($n = 15$); pediatric ($n = 3$) |
| ICU admission dates | 21 February–14 April 2020 | 20 March–13 May 2020 | Before 7 July 2020 |
| Follow-up date  | 5 May 2020             | 27 July 2020         | 7 July 2020           |

**Demographics**

|                      | Vancouver<sup>a</sup> | Montreal<sup>b</sup> | CAN-SARI<sup>c</sup> |
|----------------------|------------------------|----------------------|-----------------------|
| Female, n/total N (%) | 38/117 (32%)           | 25/75 (33%)          | 105/328 (32%)         |
| Age (yr), median [IQR] | 69 [60–75]            | 62 [53–72]          | 65 [54–72]           |
| Comorbidity, n/total N (%) |                      |                      |                       |
| Hypertension          | 54/117 (46%)           | 50/75 (67%)          | 149/328 (45%)         |
| Dyslipidemia          | 43/117 (37%)           | NR                  | NR                    |
| Diabetes mellitus     | 36/117 (31%)           | 27/75 (37%)          | 90/328 (27%)          |
| Chronic kidney disease| 15/117 (13%)           | NR                  | 67/328 (20%)          |
| None                  | 31/117 (26%)           | 11/75 (15%)          | NR                    |
| Body mass index (kg·m⁻²), median [IQR] | 28 [24–33]             | 29 [25–32]          | NR                    |
| Health care worker, n/total N (%) | NR                   | 9/75 (12%)          | NR                    |
| Severity of illness – APACHE II | 18 [10–28]             | NR                  | NR                    |
| SOFA day 1            | 6 [2–11]               | 6 [3–7]             | NR                    |
| Duration of symptoms at ICU admission (days), mean (SD) or median [IQR] | 8 (5)                  | 8 [6–11]            | 7 [3–10]<sup>a</sup> |

**ICU interventions**

|                      | Vancouver<sup>a</sup> | Montreal<sup>b</sup> | CAN-SARI<sup>c</sup> |
|----------------------|------------------------|----------------------|-----------------------|
| Invasive mechanical ventilation, n/total N (%) | 74/117 (63%)           | 43/75 (57%)          | 291/328 (89%)         |
| Duration (days), median [IQR] | 13.5 [8–22]             | 11 [5–22]            | NR                    |
| Duration (days), median [IQR], for survivors | 11 [6–16]               | 13 [5–24]            | NR                    |
| Noninvasive mechanical ventilation, n/total N (%) | 15/117 (13%)           | 16/75 (75%)          | 35/328 (11%)          |
| High-flow nasal cannula, n/total N (%) | 43/117 (37%)           | 2/75 (3%)            | 40/328 (12%)          |
| ECMO, n/total N (%) | 3/117 (3%)             | 1/75 (2%)            | 13/328 (4%)           |
| Nitric oxide, n/total N (%) | NR                    | 15/43 (36%)          | NR                    |
| Proning, n/total N (%) | 21/117 (18%)           | 11/43 (26%)          | 55/328 (17%)          |
| Tracheostomy, n/total N (%) | NR                    | 10/43 (24%)          | 10/328 (3%)           |
| Continuous renal replacement therapy, n/total N (%) | 16/117 (14%)           | 7/75 (9%)            | 49/328 (15%)<sup>b</sup> |
| Vasopressors, n/total N (%) | 65/117 (56%)           | NR                  | 274/328 (84%)         |
| Neuromuscular blockers, n/total N (%) | 50/117 (47%)           | 16/43 (38%)          | NR                    |
| Corticosteroids, n/total N (%) | 28/117 (24%)           | 35/75 (47%)          | 95/328 (29%)          |
| Deep sedation, n/total N (%) | NR                    | NR                  | NR                    |

**Outcomes**

|                      | Vancouver<sup>a</sup> | Montreal<sup>b</sup> | CAN-SARI<sup>c</sup> |
|----------------------|------------------------|----------------------|-----------------------|
| ICU LOS (days)       | 9 [5–21]               | 10 [4–19]            | NR                    |
| Hospital LOS (days)  | 18 [11–30]             | 17 [10–42]           | NR                    |
| ICU mortality, n/total N (%) | 18/117 (15%)           | 17/75 (23%)          | 86/328 (26%)          |
| Hospital mortality, n/total N (%) | 18/89 (20%)            | 19/74 (25%)          | NR                    |
| Still in ICU or hospital, n/total N (%) | 28/117 (24%)           | 1/75 (1%)            | NR                    |
| Discharge destination (survivors), n/total N (%) | NR                    | NR                  | NR                    |
Approximately 80% of patients with COVID-19 develop mild to moderate symptoms, 15% require oxygen support, and 5% progress to ARDS and multiple organ dysfunction syndrome. The SARS-CoV-2 infects type I and II pneumocytes and capillary endothelial cells. Viral uptake is promoted by TMPRSS2 (serine protease) cleavage of angiotensin converting enzyme 2 and activation of the SARS-CoV-2 spike protein. Subsequent kinin release causes vascular leak, angioedema, and coagulation activation. Hypoxemia is the culmination of endotheliitis with diffuse injury of the microcirculation, complicating thrombotic events and increased dead space ventilation; alveolitis; pulmonary edema and shunt from consolidation, and atelectasis.

Initial management of COVID-19 respiratory failure may necessitate deep coma with continuous administration of multiple sedative-hypnotic agents and use of neuromuscular blocking agents, corticosteroids, and proning. An international observational study of 2,088 ICU patients in 69 centres documented that 88% received invasive mechanical ventilation, 63% received benzodiazepines for a median [interquartile range (IQR)] of 7.0 [4.0–12.0] days, 71% received propofol for 7.0 [4.0–12.0] days, and 82% experienced deep coma for 10.0 [6.0–15.0] days. Early multicentre ICU cohort studies that enrolled 547 patients with COVID-19 in France and Belgium documented a 15 [10–25] day ICU LOS, with a 13 [9–23] day duration of mechanical ventilation. Sedation included 6 [3–12] days of midazolam and 10 [5–15] days of sufentanil; 84% received a neuromuscular blocking agent (NMBA), for 5 [2–10] days, and 80% were proned.

Proning is a proven intervention to reduce mortality in ARDS and is a cornerstone of therapy in COVID-19. The duration of daily proning in patients with COVID-19 ARDS is similar (~16 hr) to randomized controlled trials (RCTs) identified in a systematic review of moderate-to-severe ARDS (16–18 hr). Nevertheless, recurrent, daily proning requires sustained deep coma and prolonged paralytic use, which may promote muscle unloading and further exacerbate ICU-acquired weakness. A systematic review of non-COVID-19 ARDS patients showed harm from proning, including an increased risk of pressure injuries (three RCTs; 1,109 patients; relative risk, 1.22; 95% confidence interval [CI], 1.06 to 1.41) and endotracheal tube obstruction (three studies; 1,594 patients; relative risk, 1.76; 95% CI, 1.06 to 1.41). A small retrospective chart review identified that the most common upper limb nerve injuries in COVID-19 ICU survivors occurred in the ulnar nerve (40%) or brachial plexus (33%). Given the rapid uptake of prone positioning for COVID-19 ARDS, short- and long-term evaluation of post-ICU outcomes and pragmatic trials evaluating efficacy are needed.

In summary, early studies highlight the complexities of respiratory failure in patients with COVID-19: approximately two weeks of invasive mechanical ventilation, ten days of deep coma, one week of sedation, and five days of NMBA administration. Proning is common. The adoption of sustained deep coma in COVID-19 patients is in sharp contrast to current critical care guidelines recommending judicious and intermittent use of sedation, usual care with light sedation targets (Richmond Agitation and Sedation Scale between −2 to +1), and literature supporting only up to 48 hr of continuous paralytic to facilitate lung protective ventilation. For COVID-19 patients with refractory hypoxemia requiring prolonged sedation and NMBA's, further research on management strategies and long-term outcomes is needed.

Table 1 continued

| Cohort   | Vancouver* | Montreal* | CAN-SARI* |
|----------|------------|-----------|-----------|
| Home     | 71/71 (100%) |           |           |

*a* To hospital admission and median [IQR] 0 [0–1] days from hospital to ICU admission

*b* Renal replacement therapy

APACHE II = acute physiology and chronic health evaluation II, a severity of illness score where higher values (0 to 71) represent higher risk of hospital mortality; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; IQR = interquartile range; LOS = length of stay; NR = not reported; SD = standard deviation; SOFA = sequential organ failure assessment score—a measure of organ dysfunction, where higher values (0 to 24) represent higher risk of mortality.
Intensive care unit convalescent phase and emergence of ICU-acquired morbidities

Ms. Z. was mechanically ventilated for more than seven days and developed anuric renal failure requiring renal replacement therapy (RRT). As her oxygenation improved, her pharmacologic paralysis was discontinued, and her sedative and opioid analgesic infusions were weaned. Nevertheless, she remained in a coma (Richmond Agitation Sedation Scale, −4 or −5) for four more days. As she wakened, she became increasingly distressed and agitated, and delirium with attendant disorganized thinking became apparent. She was serially trialled with different antipsychotics and was effectively managed with dexmedetomidine. Once her delirium settled, she could communicate with the team and obey simple commands but had profound global weakness and was functionally quadriplegic. Her renal failure improved and she no longer required RRT. On day 11 of her ICU stay, she was extubated, and 24 hr later was discharged to the general medical floor.

Discussion and literature context

Renal injury

Renal injury in COVID-19 is common (> 40% have proteinuria at hospital admission) and acute kidney injury (AKI) affects 20–40% of critically ill patients. The renal lesion in COVID-19 is multifactorial and contributes include endotheliitis, which has been implicated in proteinuria; direct infection of the tubular endothelium causing mitochondrial dysfunction and acute tubular necrosis; immune dysregulation; and multiple organ dysfunction. There are no specific recommendations for managing AKI secondary to COVID-19. Content experts suggest implementation of the Kidney Disease: Improving Global Outcomes supportive care guideline. Development of delirium and signs of ICU-acquired weakness (ICUAW) often become apparent as patients emerge from coma. With long ICU and hospital stays, patients are at increased risk for infection, complex multimorbidities, pressure injuries, contractures, delirium, and ICUAW. This section highlights key factors associated with delirium and ICUAW. Table 2 outlines the relationship between ICU exposure/interventions in COVID-19 patients, and reported outcomes in the ICU literature.

Delirium

Delirium is defined as an acute change in level of consciousness, characterized by impaired attention and disorganized thinking. This patient experienced robust risk factors for ICU delirium including multiorgan dysfunction, mechanical ventilation, benzodiazepines, and prolonged sedation and narcotic use. Delirium is morbid and associated with longer ICU and hospital LOS, ICU, hospital and one-year mortality, and long-term cognitive impairment. The occurrence and duration of delirium are the most consistent factors associated with long-term cognitive impairment in critically ill patients.

Brain injury is common in COVID-19; prevalent neurologic symptoms have been reported in cohorts from both China and France and most commonly include headache, anosmia, and ageusia. Impaired consciousness, seizure, stroke, encephalopathy, and coma have also been described. The long-term sequelae of this injury are still emerging but commonly manifest as “brain fog” or dysexecutive syndrome and may be debilitating, limiting return to work or baseline function.

The pathophysiology of SARS-CoV-2 brain dysfunction is complex and multifactorial, including an initial extension to the central nervous system (CNS) via the transcribrial path via the olfactory epithelium to the olfactory nerve and bulb via retrograde spread through endocytotic/exocytotic transfer and fast axonal transport. Other purported mechanisms include infection of CNS glial cells via infected endothelial cells, and by infected leukocytes that cross the blood–brain barrier to infect the CNS. The pervasive endotheliitis may also provide insight into further pathophysiologic mechanisms of brain injury. A recent research letter identified large cell nuclei morphologically consistent with megacakaryocytes in cortical capillaries of patients who died of COVID-19, an observation not previously documented in the literature. From examination of post mortem brain samples from those who died from COVID-19, authors noted that these large cells may occlude capillary flow and result in a novel form of ischemic brain insult. Brain injury in the critically ill patient is further potentiated by hypoxemia and exposure to continuous infusions of sedation and opioid analgesics, intercurrent sepsis, immobility, and all the factors that mitigate delirium, including isolation from family.

A multicentre, multinational cohort study of 2,088 critically ill patients with COVID-19 represents the largest sample of the epidemiology of coma and delirium to date.
Investigators observed a high burden of acute brain dysfunction (> 80% of patients had coma and > 50% developed delirium) with a median duration of two weeks. Similar to prepandemic studies, the development of delirium was associated with mechanical ventilation, vasopressor infusions, and antipsychotics. Important modifiable determinants of delirium were benzodiazepine infusion (59% higher risk of delirium) and family visitation (27% lower risk of delirium). Hyperactive (agitated) delirium appeared to be more common, in contrast to non-COVID-19 patients who present more commonly with hypoactive delirium. Little is currently understood about the long-term effects of delirium in patients with COVID-19 and whether delirium is a risk factor for or a manifestation of specific COVID-19-related brain injury. For COVID-19 patients who develop delirium in the ICU, screening for post-ICU cognitive impairment(s) is warranted.

**Intensive care unit-acquired weakness**

Intensive care unit-acquired weakness may present as critical illness polyneuropathy (axonopathy), critical illness myopathy (myosin-depletion myopathy), or mixed critical illness neuromyopathy. It is a diagnosis of exclusion, when there is no other plausible etiology other than critical illness, and is associated with myriad risks during the ICU stay. Intensive care unit-acquired weakness may be identified by electrodiagnostic testing (e.g., nerve conduction studies, needle electromyography) or clinical exam. A clinical exam requires patient participation and is not practicable in those who are deeply sedated or unable to follow commands.

| Table 2 Overview of COVID treatment approaches, clinical observations, relationship to previous knowledge, and long-term outcome considerations |
| --- |
| Issues | COVID-19 treatments/policy changes | COVID-19 clinical observations | Knowledge from similar ICU clinical populations | Implications for long-term outcomes |
| Treatment | Dexamethasone | Improved 28-day mortality: 22.9% vs 25.5%; age-adjusted rate ratio, 0.8; 95% CI, 0.75 to 0.93; for mechanically ventilated patients: 29.3% vs 41.4%; rate ratio, 0.6; 95% CI, 0.51 to 0.81 | Corticosteroids associated with weakness | ICUAW |
| Respiratory failure | Mechanical ventilation | Incidence: 23% | Risk factor for ICUAW | ICUAW |
| | Sedation | Duration, median [IQR]: 13 [9–23] days | Barrier to mobilization | Fatigue |
| | | Duration of benzodiazepine administration, median [IQR]: 7 [4–12] days | Delirium associated with poor cognition and physical function | Cognitive impairment at hospital discharge |
| | | Duration of propofol administration, median [IQR]: 7 [4–12] days | Barrier to mobilization | ICUAW |
| | | Delirium incidence: 55% | For intubated patients: requires deep sedation and use of neuromuscular blockers | Nerve compression injuries |
| Proning | Awake proning:ongoing RCTs | Incidence in patients with COVID-19 ARDS: 79.9% | In patients with ARDS, associated with ICUAW | Nerve compression injuries |
| Neuromuscular blocking agents | Incidence in mechanically ventilated patients with COVID-19 ARDS: 84% | Risk factor for ICUAW | Cognitive impairments |
| | Duration, median [IQR]: 5 [2–10] days | Risk for PICS | Patients: Physical and cognitive impairments, mood disorders |
| ICU admission | Restricted hospital visitation policies | Family visitation (in-person or virtual): 27% reduction in risk of delirium | Risk for PICS-F | Family members: mood disorders |
| Hospital outcomes | Return to work: 60% returned by 60 days | Return to work: SARS: 35% at 3 months; 63% at 6 months; 74% at 1 year | Return to work planning; financial assistance |

ARDS = acute respiratory distress syndrome; CI = confidence interval; ICUAW = intensive care unit-acquired weakness; IQR = interquartile range; PICS = post-intensive care syndrome; PICS-F = post-intensive care syndrome, family; RCT = randomized controlled trial; SARS = severe acute respiratory syndrome
The Medical Research Council (MRC) Sum Score is a clinical examination for ICUAW. The MRC score assesses strength in six bilateral muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) and is graded from 0 (no contraction) to 5 (full strength against resistance). A sum score of < 48/60 indicates ICUAW.48 Muscles from patients with ICUAW show a shift from fast- to slow-twitch fibres, a 70% reduction in myosin, a reduction in the actin/myosin ratio, and disruption of sarcomeric architecture.49 Some disability may be fixed as recovery of muscle bulk and contractile force may be incomplete and discordant, and may have a genetic basis.49

In the pre-COVID-19 era, the median incidence of ICUAW was 39% (95% CI, 35 to 55),50 with baseline risk factors being female sex, severity of illness, and diagnosis (e.g., sepsis, multiorgan failure). Intensive care unit therapies associated with ICUAW included duration of mechanical ventilation, immobility, and receipt of NMBAs, aminoglycosides, norepinephrine, and corticosteroids.50 The 6,425-patient RCT, RECOVERY, showed improved 28-day mortality in those receiving 6 mg dexamethasone daily for up to ten days vs standard care (22.9% vs 25.7%; age-adjusted rate ratio, 0.83; 95% CI, 0.75 to 0.93).51 Effect sizes were larger for those receiving mechanical ventilation (29.3% vs 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81).51 Given the efficacy of dexamethasone in critically ill patients with COVID-19,51 the impact of corticosteroids on the development of ICUAW is potentially very important. A prepandemic systematic review of ICU patients documented ICUAW in 43% of those receiving corticosteroids vs 34% in controls (odds ratio [OR], 1.84; 95% CI, 1.26 to 2.67).52 Patients receiving mechanical ventilation and corticosteroids had twofold higher odds of developing ICUAW than those who did not (OR, 2.0; 95% CI, 1.23 to 3.27). Many patients with COVID-19 managed in the ICU have multiple risk factors for ICUAW, including mechanical ventilation, immobility, NMBAs, and corticosteroids; nevertheless, the unique contribution of COVID-19 is still under investigation. We recommend initial screening for a patient’s ability to follow simple commands53 and a clinical evaluation for ICUAW as soon as practicable in the ICU.

**Recovery from COVID-19 critical illness and long-term outcomes**

*On transfer to the medical ward, the patient was unable to stand or walk, had difficulty feeding herself, and required assistance for bathing and toileting. She commented that just sitting in a chair was exhausting. Ms. Z. was lonely and missing her family, especially her husband and ten-year-old daughter, but was not allowed visitors because of local public health policies enacted by the Canadian Quarantine Act. Two weeks later, Ms. Z. was transferred to an inpatient rehabilitation facility. Over four weeks, she had a gradual improvement in her activities of daily living and functional independence. She noted that her memory was impaired and was having difficulty processing new information and organizing her thoughts. She began to have nightmares of her ICU stay including concerns that the ICU staff were mocking/tormenting her and trying to harm her and her family members.*

*Ten weeks after her initial hospital admission, she was discharged home. She used a cane to assist with walking and balance and required a personal support worker for two hours each day to assist with bathing/toileting and meal preparation. At three months after ICU discharge, she continued to report muscle loss and ongoing weakness, most pronounced in the shoulder and hip girdle, and dependency with some activities of daily living. She noted it was still difficult to get in and out of a car, climb stairs, and bathe independently. Formal neurocognitive testing confirmed short-term memory impairment, diminished processing speed, and executive dysfunction. Her Functional Independence Measure (FIM) was 80 and her six-minute walk test (6MWT) distance was 73% of predicted. While she did not have any oxygen desaturation during exercise, her pulmonary function testing showed a mild restrictive pattern with normal diffusion capacity. She reported some days with low mood but denied symptoms of post-traumatic stress disorder (PTSD).* At six-month follow-up, she was negotiating a gradual return to work, beginning with one day per week. She requested support from a social worker to assist with her transition back to work and disability insurance paperwork. Her cognitive function was better but still impaired. Her physical function was improved but had not returned to baseline. Her FIM was 95 and her 6MWT was 82% of predicted. Her pulmonary function testing was now normal, with stable oxygenation during exercise. She reported moderate to severe depressive symptoms and agoraphobia and was seeking a psychiatry referral. Her husband was experiencing moderate anxiety and symptoms consistent with PTSD and had developed a new substance use disorder in that context. Follow-up is ongoing.

**Discussion and literature context**

Challenges with weakness, multimorbidities, impaired cognition, and altered mood may be ongoing and typical of the transformative impact of critical illness53 as well as consistent with the construct of post-intensive care
syndrome (PICS). The recent extension highlights additional conditions observed in ICU survivors, including frailty, chronic pain, endocrine and metabolic disorders (e.g., new onset diabetes), and residual fatigue.

Physical disability

Outcomes from survivors of non-COVID-19 ARDS may help us anticipate what we might expect for survivors of COVID-19. A young cohort (median age, 45 yr) of 117 survivors with severe four-quadrant ARDS (Lung Injury Severity Score, 3.7/4 and Berlin definition of moderate to severe disease) had a median [IQR] ICU LOS of 25 [15–45] days, duration of mechanical ventilation of 21 [12–40] days, and hospital LOS of 48 [27–77] days. While pulmonary function test results returned to normal or near normal by six months, patients experienced persistent physical impairment. At follow-up, the 6MWT was 49% of predicted values at three months, 64% at six months, 66% at 12 months, 68% at two years, and 76% at five years. In a cohort of SARS survivors, the 6MWT was 81% of the predicted value at three and six months, and 83% at 12 months. From a ten-centre, 391-patient cohort of non-COVID-19 survivors who were mechanically ventilated for seven or more days, the majority were unable to walk at seven days post ICU, despite being able to walk independently before their critical illness. Based on initial reports of long periods of sedation, immobilization, and subsequent slower time to initiate rehabilitation in COVID-19 ARDS ICU patients, we believe the physical disability will be at least similar to, if not worse than, non-COVID-19 ARDS, emphasizing the importance of long-term follow-up studies in survivors.

The FIM is a valid and reliable instrument typically used in inpatient rehabilitation that measures motor and cognitive disability in 18 items, using a seven-point scale (1 = total assistance; 7 = complete independence). The 13 motor items include self-care (n = 6), sphincter control (n = 2), transfers (n = 3), and locomotion (n = 2), and the five cognitive items include communication (n = 2) and social cognition (n = 3). The minimum score is 18 and the maximum score is 126, with scores < 40 reflecting maximal to total assistance, 50 reflecting moderate assistance, and > 60 reflecting modified assistance. In critically ill patients, the FIM at seven days after ICU discharge predicted the FIM score at one year, highlighting the potential for ICU interventions to mitigate modifiable long-term outcomes.

Rehabilitation

Rehabilitation interventions started in the ICU are one approach to address weakness and disability post ICU. Rehabilitation with critically ill patients is safe and feasible, even while patients receive mechanical ventilation. An early report from the UK in 110 mechanically ventilated ICU survivors of COVID-19 documented a mean time to sitting at the edge of the bed of 14 days within an ICU LOS of 22 days. These observations are similar to those from reports over a decade ago, which reported a median time from ICU admission to receipt of initial rehabilitation assessment of ten days, therapy only occurring on 14% of all ICU days, and patients unable to participate in rehabilitation because of sedation. COVID-19-related factors, including early concerns for preservation of personal protective equipment supplies, limited healthcare provider interactions with patients, delay to rehabilitation assessment and intervention, fear of healthcare worker infection, and restricted visitor policies could further increase the incidence of ICUAW and subsequent functional disability. Given the longer ICU stay and longer time to initiate ICU rehabilitation in patients with COVID-19 ARDS, preventive rehabilitation maneuvers such as careful positioning to avoid pressure injuries and joint contractures will be critical to optimize future recovery.

Long-term functional disability

Longer-term follow-up data in survivors of COVID-19 are emerging and these will inform the extent and duration of functional disability. Early research suggests important physical disability. Half of COVID-19 ICU survivors needed to learn to walk again after ICU discharge, increasing to 83% by hospital discharge. In a cohort study of 1,655 hospitalized COVID-19 survivors in China, 63% reported muscle weakness or fatigue at six months. Survivors who required high-flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation were more likely to report muscle weakness or fatigue than those not requiring supplemental oxygen (81% [95/117] vs 66% [281/424]; OR, 2.69; 95% CI, 1.46 to 4.96). At six and 12 months, the median [IQR] six-minute walk distances were 495.0 [430.0–526.0] m (82.4% predicted) and 496.5 [455.0–552.0] m (87.9% predicted), respectively, which is better than in non-COVID-19 ARDS survivors (six months, 396 [244–500] m [64% predicted]; 12 months, 422 [277–510] m [66% predicted]). Once patients are emerging from sedation and are clinically stable, we recommend documenting pre-ICU function and initiating rehabilitation. Patients will likely need to relearn fundamental mobility activities (e.g., rolling in bed, sitting at the edge of the bed, standing, walking), activities of daily living (e.g., bathing, eating), and those with prolonged intubation may be at risk for...
Mood disorders

In the late 1990s, clinical researchers began publishing on mood disturbances in post-ARDS patients including PTSD as well as depressive and nonspecific anxiety phenomena. A systematic review on psychiatric morbidity in ARDS survivors showed a median study prevalence of 28% PTSD, 28% depression, and 24% nonspecific anxiety symptoms. Prior psychiatric illness is a potent risk factor for psychiatric morbidity after ARDS. Huang et al. noted that six months after ICU discharge, survivors of COVID-19 were mainly troubled with sleep difficulties and symptoms of anxiety or depression. These outcomes were very similar to those reported in a Canadian one-year SARS follow-up. Severe acute respiratory syndrome may also be used as a case study to analyze the impact on patient recovery and mental health. Psychological impacts of SARS included “fear of infecting others, stigmatization, reduced quality of life, and posttraumatic stress.” Many of the same psychological stressors are apparent in current COVID-19 patients, survivors, and family members. Managing the mental health crisis exacerbated by COVID-19 will be a crucial step towards recovery. The COVID-19 pandemic has created novel challenges for treatment of mental illness, and many services quickly adapted to meet these needs. The Toronto Centre for Addiction and Mental Health reported an over 12-fold increase in online patient sessions from fewer than 400 in February 2020 to over 5,000 by May 2020.

Development of frailty

Frailty is a “medical syndrome with multiple causes and contributors, and is characterized by diminished strength, endurance, and reduced physiologic function that increases an individual’s vulnerability for developing increased dependency and/or death.” A patient’s frailty status may potentiate the proinflammatory response related to COVID-19 infection, predisposing to more severe infections, higher degrees of organ failure, and a poorer prognosis. Very little is known about frailty development following critical illness. A prepandemic, 567-patient longitudinal study in medical and surgical ICUs at five US centres found that the incidence of frailty increased from 24% at ICU admission to 37% at 12 months. Further, transition to a worse frailty status in those already frail occurred in 40% of patients at 12 months. Since SARS-CoV-2 infections typically require prolonged ICU stays, survivors are at higher risk for either new or worsened frailty status, and further studies are needed to understand the relationships and modifiable risk factors for frailty following COVID-19 infection. We recommend documenting the frailty status from before COVID-19 baseline and at hospital discharge to help track the patient’s longitudinal trajectory after discharge from hospital.

Impact of COVID-19-associated critical illness on family

The engagement of family as partners in the critical care environment has been shown to have significant physical, psychological, and emotional benefits for the patient and also benefits for communication and trust between care providers, LOS, and family mental health. Family presence (in person or virtual) has been shown to be the strongest predictor for reduced ICU delirium in COVID-19 patients. These potential benefits have disintegrated with the introduction of widespread visitor restriction policies via the Quarantine Act during the COVID-19 pandemic, exacerbating frustration, anxiety, and posttraumatic symptoms among patients and families. Furthermore, healthcare providers now have not only the responsibility for providing optimal care for their patients but also the added stress of balancing visitor restriction enforcement and supporting the needs of family members.

COVID-19 critical illness can also affect family members of patients with critical illness. Family members report domains of PICS, including psychological symptoms such as depression and PTSD. The prepandemic Canadian RECOVER program revealed that at seven days post ICU, 67% of caregivers of critically ill adults were at risk for clinical depression. While 84% of these caregivers showed improvement, 16% continued to have significant symptoms one year later. These data suggest that family members of patients with COVID-19 may perhaps be at even higher risk of the PICS family sequelae, and are currently an important focus of pandemic research. The second and third waves in Canada witnessed multiple patients from the same households concurrently admitted to the hospital or ICU, further amplifying the complexities of survivorship and potentially exacerbating recovery challenges. When ICU teams communicate with patients’ families, we suggest careful attention to potential indicators of mood disorders in family members. Referral of family members for further mental health supports may be necessary.
Return to work, disability insurance, and financial support

Data on return to work after COVID-19 are still emerging (Table 2), and may be confounded by increased unemployment in Canada during the pandemic. A pre-COVID-19 systematic review documented that 36% of critical illness survivors returned to work between one to three months, 64% by six months, and 60% by one year. In patients post SARS, 35% had returned to their pre-SARS level of work by three months, and 63% by six months. A 38-centre prospective cohort study from Michigan documented 60% employed full- or part-time before COVID-19 hospitalization returned to work by 60 days; however, this study was limited by a 39% follow-up rate.

For critically ill survivors and their families, disability insurance or other forms of financial support may be necessary. Canada's economic response plan offers benefits that in some cases may extend up to 26 weeks for workers who have either stopped working, had their income reduced by 50%, or are the caregiver for a family member who is sick or required to quarantine. The Canadian government created new financial support programs specifically for those affected by COVID-19, such as the Canada Recovery Benefit (CRB), Canada Recovery Sickness Benefit (CRSB), and the Canada Recovery Caregiver Benefit (CRCB). The CRB provides CAD 500 per week up to 38 weeks to those who are unemployed because of COVID-19, or had their income reduced by 50%, and do not qualify for Employment Insurance. The CRCB provides CAD 500 per week up to 38 weeks for households who have to care for a child or family member because of closures, sickness, or is required to quarantine due to COVID-19. The CRSB is a shorter-term support of up to four individual weeks to help workers infected with COVID-19 who are unable to work for at least 50% of the week.

The medical, financial, and social implications of COVID-19 have yet to fully manifest in Canada, and this disease will be responsible for the largest critically ill cohort in Canadian history. Post ARDS, the mean Canadian direct healthcare costs per patient after index hospitalization were CAD 16,200 in the first year and CAD 12,100 in the second year, primarily driven by subsequent hospitalizations, and inpatient rehabilitation. As of 19 November 2021, the Public Health Agency of Canada reported 17,574 patients admitted to ICUs during the COVID-19 pandemic, based on hospitalization data available for 72.8% of over 1.75 million cases. If we consider data from Canadian ARDS survivors, assuming a 75% COVID-19 ICU survival rate for 13,180 patients, and conservative estimate of 50% disability rate post ICU, the minimum two-year post-ICU healthcare costs alone are over 186 million, posing an important policy implication for our Canadian healthcare system to manage post-intensive care sequelae of this group alone. While financial support is crucial to those affected by COVID-19, psychological and physical rehabilitation will play key roles in the recovery of critically ill COVID-19 patients.

How can we prepare for the future? Summary and conclusions

Surviving an ICU stay for COVID-19 is the start of a complex road to physical, cognitive, and psychological recovery. We summarize key messages in Table 3. The emerging practice patterns documented for critically ill mechanically ventilated patients with COVID-19, including prolonged sedation, delirium, and ICUAW, are associated with important long-term morbidity in non-COVID-19 patients. COVID-19 may amplify and exacerbate these negative sequelae and may introduce new challenges for survivors, their families, and healthcare providers. Future understanding of context-specific exceptions for visitors will inform future decisions on balancing the risk and benefits of family partners and patient-centred care.

COVID-19 will serve to encourage careful consideration of establishing longitudinal programs for survivors of critical illness and their families, and rigorous follow up is urgently needed. In the hospital setting and beyond, future research is needed for a post ICU continuum of care to improve care transitions and systematically address the physical and neuropsychological sequelae of severe illness, immediate rehabilitation needs, and the longer-term assistance with return to community. As patients and their families navigate their recovery from critical illness, research and support to help them return to their lives and communities will be critically important.

Footnote continued

A Government of Canada. COVID-19 daily epidemiology update. Available from URL: https://health-infobase.canada.ca/covid-19/
Table 3 Key messages

| Issue             | Key message                                                                                                                                 |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Delirium          | For COVID-19 patients who develop delirium in the ICU, screening for post-ICU cognitive impairment(s) is warranted                                |
| ICU-acquired weakness | We recommend initial screening for a patient’s ability to follow simple commands and a clinical evaluation for intensive care unit-acquired weakness as soon as practicable in the ICU |
| Physical disability | Once patients are emerging from sedation and are clinically stable, we recommend documentation of pre-ICU function and initiation of rehabilitation. Patients will likely need to relearn fundamental mobility activities, activities of daily living, and those with prolonged intubation may be at risk for dysphagia. We recommend engaging rehabilitation professionals in the ICU and on the wards, depending on patients’ needs and availability of hospital staff |
| Frailty           | We recommend documentation of frailty status at pre-COVID-19 baseline and at hospital discharge to help track the patient’s longitudinal trajectory after hospital discharge |
| Family            | When ICU teams communicate with patients’ families, we suggest careful attention to potential indicators of mood disorders in family members. Referral of family members for further mental health support may be necessary |

ICU = intensive care unit

Author contributions  Michelle E. Kho and Margaret S. Herridge contributed to all aspects of this manuscript, including study conception and design; acquisition, analysis, and interpretation of data; and drafting the article. Oleksa Rewa, J. Gordon Boyd, Karen Choong, and Graeme C.H. Stewart contributed to the study design; acquisition, analysis, and interpretation of data; drafting sections of the manuscript; and approval of the submitted work.

Commercial or noncommercial affiliations that are or may be perceived to be a conflict of interest with the work for each author  Michelle Kho leads a research program of early in-bed cycling with critically ill patients and received the loan of four in-bed cycles from Restorative Therapies, Baltimore, MD. J Gordon Boyd receives a stipend from the Trillium Gift of Life Network to support his role as Regional Medical Lead.

Funding statement  Michelle Kho is funded by a Canada Research Chair. Michelle Kho, J Gordon Boyd, and Margaret Herridge hold CIHR grants related to the submitted work.

Consultancies  Oleksa Rewa has received consultation fees from Baxter Healthcare Inc.

Editorial responsibility  This submission was handled by Dr. Stephan K.W. Schwarz, Editor-in-Chief, Canadian Journal of Anesthesia/Journal canadien d’anesthésie.

References

1. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia 2020; 75: 1340-9.
2. Armstrong RA, Kane AD, Kursunovic E, Oglesby FC, Cook TM. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia 2021; 76: 537-48.
3. Rees EM, Nightingale ES, Jafari Y, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med 2020; DOI: https://doi.org/10.1186/s12916-020-01726-3.
4. Verma AA, Hora T, Jung HY, et al. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. CMAJ 2021; 193: E410-8.
5. Cavayas YA, Noel A, Brunette V, et al. Early experience with critically ill patients with COVID-19 in Montreal. Can J Anesth 2021; 68: 204-13.
6. Mitra AR, Ferguson NA, Lloyd-Smith E, et al. Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series. CMAJ 2020; 192: E694-701.
7. Herridge MS, Cha LM, Matte A, et al. The RECOVER program: disability risk groups and 1-year outcome after 7 days or more of mechanical ventilation. Am J Respir Crit Care Med 2016; 194: 831-44.
8. Needham DM, Davidson J, Cohen H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders’ conference. Crit Care Med 2012; 40: 502-9.
9. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: decipher pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9: 622-42.
10. Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicenter cohort study. Lancet Respir Med 2021; 9: 239-50.
11. Helms J, Kremer S, Merdji H, et al. Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. Crit Care 2020; DOI: https://doi.org/10.1186/s13054-020-03200-1.
12. Courcelle R, Gaudry S, Serck N, et al. Neuromuscular blocking agents (N MBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study. Crit Care 2020; DOI: https://doi.org/10.1186/s13054-020-03164-2.
13. Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368: 2159-68.
14.Gattinoni L, Togponi G, Pesenti A, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001; 345: 568-73.
15. Venus K, Munshi L, Fralick M. Prone positioning for patients with hypoxic respiratory failure related to COVID-19. CMAJ 2020; 192: E1532-7.
16. Stilma W, van Meenen DM, Valk CM, et al. Incidence and practice of early prone positioning in invasively ventilated COVID-19 patients-insights from the PRoVENT-COVID
observational study. J Clin Med 2021; DOI: https://doi.org/10.3390/jcm10204783.
17. Aoyama H, Uchida K, Aoyama K, et al. Assessment of therapeutic interventions and lung protective ventilation in patients with moderate to severe acute respiratory distress syndrome: a systematic review and network meta-analysis. JAMA Netw Open 2019; DOI: https://doi.org/10.1001/jamanetworkopen.2019.8116.
18. Munshi L, Del Sorbo L, Adhikari NK, et al. Prone position for acute respiratory distress syndrome. a systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14(Supplement_4): S280-8.
19. Miller C, O’Sullivan J, Jeffrey J, Power D. Brachial plexus neuropathies during the COVID-19 pandemic: a retrospective case series of 15 patients in critical care. Phys Ther 2021; DOI: https://doi.org/10.1093/ptj/pzaa191.
20. Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018; 46: e825-73.
21. Mehta S, Burly L, Cook D, et al. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA 2012; 308: 1985-92.
22. Tarazan N, Alshehri M, Sharif S, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials. Intensive Care Med Exp 2020; DOI: https://doi.org/10.1186/s40635-020-00348-6.
23. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97: 829-38.
24. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323: 2052-9.
25. Ronco C, Reix T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med 2020; 8: 738-42.
26. Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1-138.
27. Latibeaudiere SO, Afonso E, Benbenishty J, et al. Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubiICUs study. Intensive Care Med 2021; 47: 160-9.
28. Clavet H, Hebert PC, Fergusson D, Doucette S, Trudel G. Joint contracture following prolonged stay in the intensive care unit. CMAJ 2008; 178: 691-7.
29. Brummel NE, Jackson JC, Pandharipande PP, et al. Delirium in the ICU and subsequent long-term disability among survivors of mechanical ventilation. Crit Care Med 2014; 42: 369-77.
30. Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. Crit Care 2008; DOI: https://doi.org/10.1186/cc6149.
31. Zaal IJ, Devlin JW, Peelen LM, Slooter AJ. A systematic review of risk factors for delirium in the ICU. Crit Care Med 2015; 43: 40-7.
32. Goldberg TE, Chen C, Wang Y, et al. Association of delirium with long-term cognitive decline: a meta-analysis. JAMA Neurol 2020; 77: 1373-8.
33. Pandharipande PP, Girard TD, Ely EW. Long-term cognitive impairment after critical illness. N Engl J Med 2014; 370: 185-6.
34. Sakusic A, O’Horo JC, Dzidzko M, et al. Potentially modifiable risk factors for long-term cognitive impairment after critical illness: a systematic review. Mayo Clin Proc 2018; 93: 68-82.
35. Mao L, Jin H, Wang M, et al. Neuromuscular manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683-90.
36. Helms J, Kremers S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382: 2268-70.
37. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020; 77: 1018-27.
38. Nauen DW, Hooper JE, Stewart CM, Solomon IH. Assessing brain capillaries in coronavirus disease 2019. JAMA Neurol 2021; 78: 760-2.
39. Hopkins RO, Weaver LK, Pope D, Orme JF, Bigler ED, Larson-Lohr V. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160: 50-6.
40. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010; 304: 1787-94.
41. Hopkins RO, Suchyta MR, Farrer TJ, Needham D. Improving post-intensive care unit neuropsychiatric outcomes: understanding cognitive effects of physical activity. Am J Respir Crit Care Med 2012; 186: 1220-8.
42. Peritogiannis V, Bolosi M, Lixouriots C, Rizos DV. Recent insights on prevalence and corelations of hypoactive delirium. Behav Neurol 2015; DOI: https://doi.org/10.1155/2015/416792.
43. Lad H, Saumur TM, Herridge MS, et al. Long-term cognitive impairment after critical illness: recent insights. Crit Care 2021; DOI: https://doi.org/10.1186/cc6149.
44. Yang T, Li Z, Jiang L, Xi X. Risk factors for intensive care unit-acquired weakness: a systematic review and meta-analysis of randomized trials. Int J Mol Sci 2020; DOI: https://doi.org/10.3390/ijms2121840.
45. Latronico N, Feni F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996; 347: 1579-82.
46. De Jonghe B, Sharbar T, Lejaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288: 2859-67.
47. Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 2009; 37: S299-308.
48. Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med 2014; 371: 287-8.
49. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991; 14: 1103-9.
50. Dos Santos C, Hussain SN, Mathur S, et al. Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay. A pilot study. Am J Respir Crit Care Med 2016; 194: 821-30.
51. Yang T, Li Z, Jiang L, Wang Y, Xi X. Risk factors for intensive care unit-acquired weakness: a systematic review and meta-analysis. Acta Neurol Scand 2018; 138: 104-14.
52. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2020; 384: 693-704.
53. Yang T, Li Z, Jiang L, Xi X. Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis. Crit Care 2018; DOI: https://doi.org/10.1186/s13054-018-2111-0.
54. Urowe M, Kahn JM, Carson SS, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med 2010; 153: 167-75.
55. Rousseau AF, Prescott HC, Brett SJ, et al. Long-term outcomes after critical illness: recent insights. Crit Care 2021; DOI: https://doi.org/10.1186/s13054-021-03555-3.
56. Herridge MS, Cheung AM, Tunsey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348: 683-93.
56. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011; 364: 1293-304.

57. Cheung AM, Tansey CM, Tomlinson G, et al. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 174: 538-44.

58. Tansey CM, Loeu M, Loeb M, et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med 2007; 167: 1312-20.

59. Dodds TA, Martin DP, Stolow WC, Deyo RA. A validation of the functional independence measurement and its performance among rehabilitation inpatients. Arch Phys Med Rehabil 1993; 74: 531-6.

60. Ottenbacher KJ, Hsu Y, Granger CV, Fiedler RC. The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehabil 1996; 77: 1226-32.

61. Nydahl P, Sricharoenchai T, Chandra S, et al. Safety of patient mobilization and rehabilitation in the intensive care unit. Systematic review with meta-analysis. Ann Am Thorac Soc 2017; 14: 766-77.

62. Waldauf P, Jirovská K, Krajcová A, Pathucheary Z, Duska F. Effects of rehabilitation interventions on clinical outcomes in critically ill patients: systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2020; 48: 1055-65.

63. Takaoka A, Utgikar R, Rochwerg B, Cook DJ, Kho ME. The efficacy and safety of in-intensive care unit leg-cycle ergometry in critically ill adults. A systematic review and meta-analysis. Ann Am Thorac Soc 2020; 17: 1289-307.

64. Mc-Williams D, Weblin J, Hodson J, Veenith T, Whitehouse T, Snelson C. Rehabilitation levels in patients with COVID-19 admitted to intensive care requiring invasive ventilation. An observational study. Ann Am Thorac Soc 2021; 18: 122-9.

65. Zanni JM, Korupolu R, Fan E, et al. Rehabilitation therapy and outcomes in acute respiratory failure: an observational pilot project. J Crit Care 2010; 25: 254-62.

66. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-32.

67. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet 2021; 398: 747-58.

68. Hodgson CL, Seville K, Needham DM, et al. Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults. Crit Care 2014; DOI: https://doi.org/10.1186/s13054-014-0658-y.

69. Osbeck Sandblom H, Dotevall H, Svennerholm K, Tuomi L, Finizzi C. Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU-an observational clinical study. PLoS One 2021; DOI: https://doi.org/10.1371/journal.pone.0252347.

70. Davydov DS, Desai SV, Needham DM, Bienvenu OJ. Psychiatric morbidity in survivors of the acute respiratory distress syndrome: a systematic review. Psychosom Med 2008; 70: 512-9.

71. Davydov DS, Gifford JM, Desai SV, Bienvenu OJ, Needham DM. Depression in general intensive care unit survivors: a systematic review. Intensive Care Med 2009; 35: 796-809.

72. Davydov DS, Gifford JM, Desai SV, Needham DM, Bienvenu OJ. Posttraumatic stress disorder in general intensive care unit survivors: a systematic review. Gen Hosp Psychiatry 2008; 30: 421-34.

73. Gardner PJ, Moaalef P. Psychological impact on SARS survivors: critical review of the English language literature. Can Psychol 2015; 56: 123-35.

74. Centre for Addiction and Mental Health. COVID-19 pandemic adversely affecting mental health of women and people with children; 2020. Available from URL: https://www.camh.ca/en/camh-news-and-stories/covid-19-pandemic-adversely-affecting-mental-health-of-women-and-people-with-children (accessed November 2021).

75. Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013; 14: 392-7.

76. Pansarasoa O, Pistono C, Davin A, et al. Altered immune system in frailty:genetics and diet may influence inflammation. Ageing Res Rev 2019; DOI: https://doi.org/10.1016/j.arr.2019.100935.

77. Brummel NE, Girard TD, Pandharipande PP, et al. Prevalence and course of frailty in survivors of critical illness. Crit Care Med 2020; 48: 1419-26.

78. Goldfarb MI, Bibas L, Bartlett V, Jones H, Khan N. Outcomes of patient- and family-centered care interventions in the ICU: a systematic review and meta-analysis. Crit Care Med 2017; 45: 1751-61.

79. Government of Canada. Consolidated Federal Laws of Canada, Quarantine Act - 2005. Available from URL: https://laws-lois.justice.gc.ca/eng/acts/q-1.1/FullText.html (accessed November 2021).

80. Munshi L, Evans G, Razak F. The case for relaxing no-visitor policies in hospitals during the ongoing COVID-19 pandemic. CMAJ 2021; 193: E135-7.

81. Cameron JI, Chu LM, Matte A, et al. One-year outcomes in caregivers of critically ill patients. N Engl J Med 2016; 374: 1831-41.

82. Kandar BR, Suri R, Suchyta MR, et al. Return to work after critical illness; a systematic review and meta-analysis. Thorax 2020; 75: 17-27.

83. Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med 2021; 174: 576-8.

84. Government of Canada; Department of Finance Canada. Canada’s COVID-19 Economic Response Plan: Support for Canadians and Businesses. Available from URL: https://www.canada.ca/en/department-finance/news/2020/03/canadas-covid-19-economic-response-plan-support-for-canadians-and-businesses.html (accessed November 2021).

85. Murthy S, Archambault PM, Atique A, et al. Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. CMAJ Open 2021; 9: E181-8.

86. Rochwerg B, Oczkowski SJ, Siemieniuk RA, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Crit Care Med 2018; 46: 1411-20.

87. Patel U, Malik P, Usman MS, et al. Age-adjusted risk factors associated with mortality and mechanical ventilation utilization amongst COVID-19 hospitalizations-a systematic review and meta-analysis. SN Compr Clin Med 2020; DOI: https://doi.org/10.1007/s42399-020-00476-w.

88. Koo KK, Choong K, Cook DJ, et al. Early mobilization of critically ill adults: a survey of knowledge, perceptions and practices of Canadian physicians and physiotherapists. CMAJ Open 2016; 4: E448-54.

89. Reddy MP, Subramanium A, Lim ZJ, et al. Prone positioning of non-intubated patients with COVID-19 - a systematic review and meta-analysis. medRxiv 2020; DOI: https://doi.org/10.1101/2020.10.12.211748.

90. Valley TS, Schutz A, Nagle MT, et al. Changes to visitation policies and communication practices in Michigan ICUs during the COVID-19 pandemic. Am J Respir Crit Care Med 2020; 202: 883-5.
91. Herridge MS, Moss M, Hough CL, et al. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med 2016; 42: 725-38.

92. Hill AD, Fowler RA, Pinto R, Herridge MS, Cuthbertson BH, Scales DC. Long-term outcomes and healthcare utilization following critical illness—a population-based study. Crit Care 2016; DOI: https://doi.org/10.1186/s13054-016-1248-y.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.